Borderline High LDL Cholesterol (130–159 mg/dL): Risk Assessment and Management

LDL-C 130–159 mg/dL is classified as “borderline high” (NCEP ATP III / ACC/AHA). While not a treatment threshold for pharmacotherapy in low-risk individuals, it warrants risk assessment and lifestyle intervention.

Risk Context

• LDL is causal for atherosclerosis: each 1 mmol/L (38.7 mg/dL) reduction → ~22% relative risk reduction in major vascular events (CTT meta-analysis).
• Borderline LDL contributes to lifetime risk, especially with other factors: hypertension, smoking, diabetes, low HDL, family history, age, ethnicity.

10-Year ASCVD Risk Calculator (Pooled Cohort Equations)

• <5% (low risk): Lifestyle only; repeat lipids 3–5 years.
• 5–7.5% (borderline): Lifestyle; consider risk enhancers (family history, Lp(a), hs-CRP, CAC score).
• ≥7.5% (intermediate): Moderate-intensity statin + lifestyle.
• ≥20% (high): High-intensity statin.

Lifestyle Interventions (First-Line)

• Mediterranean/DASH diet: ↑ fiber, nuts, olive oil, fatty fish; ↓ saturated fat, trans fat, refined carbs.
• Plant sterols/stanols 2 g/day → ↓ LDL 5–10%.
• Soluble fiber 5–10 g/day (oats, beans, psyllium) → ↓ LDL 5–10%.
• Exercise: 150 min moderate/week + resistance 2×/week.
• Weight loss: 5–10% body weight → ↓ LDL 5–15%.
• Smoking cessation, alcohol moderation.

When to Consider Statin

• LDL ≥190 mg/dL (any risk)
• Diabetes age 40–75
• ASCVD risk ≥7.5% + risk enhancers
• CAC score ≥100 Agatston or ≥75th percentile
• Clinical ASCVD (secondary prevention)

Follow-Up

Recheck lipid panel 4–12 weeks after lifestyle change; if on statin, 4–12 weeks after initiation/titration. Target: ≥30% LDL reduction (moderate statin) or ≥50% (high-intensity).